Unlock stock picks and a broker-level newsfeed that powers Wall Street.

BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations · Investor's Business Daily

In This Article:

BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter on the market.